Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Geography

Description

Global insulin glargine market is estimated to be valued at USD 5.45 Bn in 2024 and is expected to reach USD 8.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 5.45 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	6.40%	2030/2031 Value Projection:	US$ 8.43 Bn

Insulin Glargine Market Share (%), By Region, 2024

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

Type:
- Lantus
- Basaglar
- Toujeo
- Soliqua/Suliqua
- Others
Diabetes Type:
- Type 2 Diabetes
- Type 1 Diabetes
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Sanofi
- Biocon
- Eli Lilly and Company
- Boehringer Ingelheim
- Gan & Lee
- Kalbe Pharma
- Polus Biopharm
- Samsung Bioepis
- Wockhardt
- Novo Nordisk AS
- Julphar
- Viatris Inc.

Product Code: CMI5231

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diabetes Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Insulin Glargine Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Insulin Glargine Market, By Type, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Basaglar
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Toujeo
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Soliqua/Suliqua
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Insulin Glargine Market, By Diabetes Type, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Insulin Glargine Market, By Distribution Channel, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Insulin Glargine Market, By Region, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kalbe Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Polus Biopharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact